Overview

Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone

Status:
Unknown status

Trial end date:
2013-03-01

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate the safety of biological active dose of a new experimental drug, IL-7, in combination with standard bi-therapy in patients with Hepatitis C chronic infection identified as non responders to the standard bi-therapy alone.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Cytheris SA

Treatments:

Interferons
Ribavirin